L-Ascain Dosage/Direction for Use



Dexa Medica


Averroes Pharma
Full Prescribing Info
Dosage/Direction for Use
The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should always be used. The smallest dose and concentration required to produce the desired result should be administered. The dose of any local anesthetic differs with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the intensity of the block, the degree of muscle relaxation required, the duration of the anesthesia desired, individual tolerance, and the physical condition of the patient. Patients in poor general condition due to aging or other compromising factors, such as impaired cardiovascular function, advanced liver disease, or several renal dysfunction, require special attention.
To reduce the risk of potentially serious adverse reactions, attempts should be made to optimize the patient's condition before major blocks are performed, and the dosage should be adjusted accordingly. Use an adequate test dose (3 to 5 ml) of a short-acting local anesthetic solution containing epinephrine prior to induction ofcomplete nerve block. This test dose should be repeated if the patient is moved in such a fashion as to have displaced the epidural catheter. It is recommended that adequate time be allowed for the onset of anesthesia following administration of each test dose.
The use of levobupivacaine hydrochloride monohydrate is not recommended for more than 24 hours (see Precautions).
Disinfecting agents containing heavy metals, which cause release of ions (mercury, zinc, copper, etc.) should not be used for skin or mucous membrane disinfection since they have been related to incidents of swelling and edema.
When chemical disinfection of the container surface is desired, either isopropyl alcohol (91%) or ethyl alcohol (70%) is recommended. It is recommended that chemical disinfection be accomplished by wiping the ampule thoroughly with cotton or gauze that has been moistened with the recommended alcohol prior to use.
These products are intended for single use and do not contain preservatives; any solution remaining from an open container should be discarded. For specific techniques and procedures, refer to standard contemporary textbooks.
Levobupivacaine hydrochloride monohydrate compatibility: Levobupivacaine hydrochloride monohydrate is compatible with 0.9% sodium chloride injection.
Dilution stability: After dilution in 0.9% sodium chloride solution, levobupivacaine hydrochloride monohydrate is physically and chemically stable at temperature 30°C for 7 days. Aseptic technique should be used to prepare the diluted products. Admixtures of levobupivacaine should be prepared for single patient use only. The unused portion of diluted levobupivacaine hydrochloride monohydrate should be discarded after each use.
From a microbiological poin of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C.
Note: parenteral products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Solutions that are not clear and colorless should not be used. (See Table 1.)

Click on icon to see table/diagram/image

Epidural doses of up to 375 mg have been administered incrementally to patients during a surgical procedure.
The maximum dose in 24 hours for intraoperative block and postoperative pain management was 695 mg.
The maximum dose administered as a postoperative epidural infusion over 24 hours was 570 mg.
The maximum dose administered to patients as a single fractionated injection was 300 mg for brachial plexus block.
For Caesarean section, the maximum recommended dose is 150 mg.
In children, the maximum recommended dose for infiltration analgesia (ilioinguinal-iliohypogastric block) is 1.25 mg/kg/side.
Route of Administration: For parenteral use.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in